JOP20200284A1 - حمض نووي لعلاج حساسية القشريات - Google Patents

حمض نووي لعلاج حساسية القشريات

Info

Publication number
JOP20200284A1
JOP20200284A1 JOP/2020/0284A JOP20200284A JOP20200284A1 JO P20200284 A1 JOP20200284 A1 JO P20200284A1 JO P20200284 A JOP20200284 A JO P20200284A JO P20200284 A1 JOP20200284 A1 JO P20200284A1
Authority
JO
Jordan
Prior art keywords
nucleotide sequence
sequence encoding
nucleic acid
lit
domain
Prior art date
Application number
JOP/2020/0284A
Other languages
English (en)
Inventor
Marui Takanori
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JOP20200284A1 publication Critical patent/JOP20200284A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير حمض نووي متوقع أن يكون مفيدًا لعلاج حساسية القشريات. ويتوفر حمض نووي يشمل متوالية نوكليوتيد تشفر بروتين خيمري، حيث يشتمل الحمض النووي على متوالية نوكليوتيد تشفر ببتيد إشارة، متوالية نوكليوتيد تشفر مجال تثبيت LAMP داخل العضيات، متوالية نوكليوتيد تشفر مجال مولد حساسية يشمل Lit v 1، Lit v 4، وLit v 3، متوالية نوكليوتيد تشفر مجال عبر الغشاء ومتوالية نوكليوتيد تشفر مجال LAMP يستهدف جسيم داخلي/ جسيم حال.
JOP/2020/0284A 2018-05-11 2019-05-10 حمض نووي لعلاج حساسية القشريات JOP20200284A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018091989 2018-05-11
PCT/JP2019/018659 WO2019216396A1 (ja) 2018-05-11 2019-05-10 甲殻類アレルギー治療のための核酸

Publications (1)

Publication Number Publication Date
JOP20200284A1 true JOP20200284A1 (ar) 2020-11-09

Family

ID=68468131

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0284A JOP20200284A1 (ar) 2018-05-11 2019-05-10 حمض نووي لعلاج حساسية القشريات

Country Status (17)

Country Link
US (1) US20210163549A1 (ar)
EP (1) EP3792361A4 (ar)
JP (1) JPWO2019216396A1 (ar)
KR (1) KR20210007981A (ar)
CN (1) CN112119161A (ar)
AU (1) AU2019268024A1 (ar)
BR (1) BR112020023031A2 (ar)
CA (1) CA3099505A1 (ar)
CO (1) CO2020013963A2 (ar)
JO (1) JOP20200284A1 (ar)
MA (1) MA52584A (ar)
MX (1) MX2020012055A (ar)
PH (1) PH12020551877A1 (ar)
SG (1) SG11202011166UA (ar)
TW (1) TW202016311A (ar)
WO (1) WO2019216396A1 (ar)
ZA (1) ZA202006985B (ar)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587994B2 (ja) 1977-09-22 1983-02-14 エプソン株式会社 液晶表示装置
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
WO2002080851A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines
US20120219545A1 (en) * 2009-07-31 2012-08-30 Mount Sinai School Of Medicine Materials and methods for diagnosing and treating shellfish allergy
TWI548982B (zh) 2012-03-06 2016-09-11 宏碁股份有限公司 管理方法及相關電腦系統及其電腦程式產品
DK2861240T3 (da) * 2012-06-15 2020-09-28 Immunomic Therapeutics Inc Nukleinsyrer til behandling af allergier
CN106662578B (zh) * 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
JP2015200357A (ja) 2014-04-07 2015-11-12 本田技研工業株式会社 車両用動力伝達装置
WO2015200357A2 (en) 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10301365B2 (en) * 2015-10-14 2019-05-28 The Chinese University Of Hong Kong Met e 1 tropomyosin variants for use in allergen-specific immunotherapy
JP7078620B2 (ja) * 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸

Also Published As

Publication number Publication date
CO2020013963A2 (es) 2021-02-08
PH12020551877A1 (en) 2021-05-31
AU2019268024A1 (en) 2020-11-26
WO2019216396A1 (ja) 2019-11-14
EP3792361A4 (en) 2022-01-26
SG11202011166UA (en) 2020-12-30
ZA202006985B (en) 2022-03-30
BR112020023031A2 (pt) 2021-02-09
TW202016311A (zh) 2020-05-01
EP3792361A1 (en) 2021-03-17
JPWO2019216396A1 (ja) 2021-05-27
US20210163549A1 (en) 2021-06-03
MX2020012055A (es) 2021-01-29
CN112119161A (zh) 2020-12-22
MA52584A (fr) 2021-03-17
KR20210007981A (ko) 2021-01-20
CA3099505A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
GB2569734A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2021015182A (es) Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso.
MX2020005127A (es) Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados.
WO2018093932A3 (en) Nucleic acids for treatment of allergies
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
CY1111324T1 (el) Πρωτεϊνες συντηξης
WO2020198509A3 (en) Modified oligonucleotides with increased stability
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
WO2006059093A3 (en) Fusion proteins
WO2015200357A3 (en) Nucleic acids for treatment of peanut allergies
MX2020001282A (es) Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion.
NZ596735A (en) Recombinant production of peptides
WO2020127532A3 (en) Rna encoding a protein
WO2016130628A8 (en) Griffithsin mutants
MX2021005313A (es) Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
MX2018011834A (es) Expresión de proteínas en bacterias gram negativas en la que la relación del volumen periplasmático con respecto al volumen citoplasmático está entre 0.5:1 y 10:1.
JOP20200285A1 (ar) حمض نووي لعلاج حساسية العث
JOP20200284A1 (ar) حمض نووي لعلاج حساسية القشريات
SG10201809464RA (en) Antibody gene expression-secretion system
WO2009021000A3 (en) Protein and dna sequence encoding a cold adapted subtilisin-like activity
MX2017016501A (es) Aminopeptidasas para hidrolizados de proteinas.
MY160224A (en) Signal peptide contained in mannose-specific lectin precursor, nucleic acid encoding the signal peptide, and use of the signal peptide and the nucleic acid
ATE420950T1 (de) Verfahren zur herstellung von lipasen
KR20040053279A (ko) 스트레스 저항성 및 내성 단백질을 코딩하는 유전자